Literature DB >> 10820131

Short communication. The effects of drinking and smoking on the CYP2D6 metabolic capacity.

M Vincent-Viry1, B Fournier, M M Galteau.   

Abstract

We studied the influence of drinking and smoking habits on CYP2D6 metabolic capacity measured by the use of debrisoquine as a substance test. We did not find any significant differences in the frequency of subjects with CYP2D6 deficiency (poor metabolizers) among four groups of healthy individuals: nonsmokers/nondrinkers, smokers/drinkers, nondrinkers/smokers, and nonsmokers/drinkers. We demonstrated that, among poor metabolizers, alcohol and tobacco consumption was associated with higher metabolic ratios than it was with the control group, but the differences were not statistically significant. Among extensive metabolizers, the lowest metabolic ratio (highest enzyme activity) was detected for nondrinkers/smokers, intermediate values for smokers/drinkers, and the highest metabolic ratio (lowest enzyme activity) for nonsmokers/drinkers. These variations were slight but statistically significant when logarithmic ratio values were applied. These results show that smoking and drinking habits do not need to be taken into account when humans are phenotyped for CYP2D6.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10820131

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  3 in total

1.  3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.

Authors:  Yueying Zhen; Ondrej Slanar; Kristopher W Krausz; Chi Chen; Josef Slavík; Kerry L McPhail; T Mark Zabriskie; Frantisek Perlík; Frank J Gonzalez; Jeffrey R Idle
Journal:  Drug Metab Dispos       Date:  2006-06-16       Impact factor: 3.922

2.  Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects.

Authors:  Christian Funck-Brentano; Pierre-Yves Boëlle; Céline Verstuyft; Célia Bornert; Laurent Becquemont; Jean-Marie Poirier
Journal:  Eur J Clin Pharmacol       Date:  2005-11-17       Impact factor: 2.953

3.  Sex, estrous cycle, and hormone regulation of CYP2D in the brain alters oxycodone metabolism and analgesia.

Authors:  Nicole Arguelles; Janielle Richards; Ahmed A El-Sherbeni; Sharon Miksys; Rachel F Tyndale
Journal:  Biochem Pharmacol       Date:  2022-02-07       Impact factor: 6.100

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.